109 results
Page 2 of 6
6-K
EX-99.1
sbky681sbl
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-1.1
b2on78s666n7y35vd9
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
aofufnmz5n4 k1nwub7
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
8qrtqxl4wqfasfpeca8a
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
6-K
EX-99.1
tz6r3dja3lmbt
8 May 23
Report of Foreign Private Issuer
8:23am
6-K
EX-10.3
8cem3p 3gnetom8trk
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
6-K
EX-99.1
dzydc2vl
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.6
c66t8axphwilirk
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.3
o87wy21vgxdl
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.1
ao0sj
25 Aug 22
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment
6:54am
6-K
EX-99.1
jpwbqx gbqpleuakwb
2 Aug 22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
4:00pm
6-K
EX-99.1
dtwckqluxzs6k
2 Jun 22
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
16v19nfiyer6jcjn
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.4
1ry6r8ash3 37
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.2
pgrbgx 8id58uq
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.1
d6u4itr dw4x5egyk
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am
6-K
EX-99.1
d1ywuvzy
24 May 22
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
8:31am
6-K
EX-99.1
eilsq
11 May 22
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
1:58pm